Studies Discover Biomarkers for Early Heart Disease
News Sep 15, 2005
Applied Biosystems, an Applera Corporation business has announced that findings from research studies presented at the 12th Annual Chips to Hits® Conference report the discovery of biomarkers in several diseases, including early heart disease and thyroid cancer, using its advanced gene expression technologies.
Preliminary data from Harvard Medical School identified several genes that may play a critical role in the development of early heart disease.
Researchers are investigating three biomarkers that may indicate healthy endothelium or blood vessel lining.
"Dysfunctional endothelium lining is a primary cause of heart disease. Studying the genetic underpinnings of blood vessel lining will help us identify the molecular operations of early heart disease," said Guillermo Garcia-Cardena, Ph.D., Assistant Professor of Pathology, Harvard Medical School.
"With Applied Biosystems Expression Array System, we have been able to characterize distinct phenotypes at the molecular level and identify novel genes bringing us closer to understanding heart disease."
Data from Trinity College Dublin evaluated key biomarkers for Papillary Thyroid Cancer, the most common form of thyroid cancer, using the Applied Biosystems Expression Array System.
Findings confirm identified biomarkers have the potential to significantly improve diagnostic accuracy and prognostics of thyroid cancer.
"As our latest generation of gene expression technologies, including our Expression Array System, TaqMan® Genomic Assays, TaqMan® Low Density Arrays, and Real-Time PCR systems, continue to gain traction in the industry, we are delighted to see exciting results being generated by researchers in important areas, such as biomarker identification. These biomarkers may result in clinical diagnostics and targeted therapeutics for serious diseases," said Dennis A. Gilbert, Ph.D., Chief Scientific Officer for Applied Biosystems.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.